MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL.
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET.
Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.
Incyte said on Monday it has agreed to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its pipeline for blood disorder therapies.